Safeguard the Right-To-Try Cutting-Edge Medicine Act

Removed navigation links, headers, and formatting artifacts from the legislative text, converting from a markup document to clean plain text.

Reorganized section numbering and removed page markers and committee substitute labels while maintaining the same substantive legal provisions.

Added a note explaining the bill's purpose and clarified that liability for treatment expenses extends to the patient's estate unless a contract states otherwise.

Added requirement that eligible patients must be unable to participate in clinical trials within 100 miles of their home or not accepted to such trials within one week of application completion.

Added exclusion preventing patients currently treated as inpatients in licensed hospitals from qualifying for the right-to-try program.

Expanded definition of investigational products to include drugs that successfully completed phase one clinical trials but lack FDA approval.

Added requirement for informed consent documents to include statement that in-home health care may be denied if treatment begins.

Removed detailed provisions about hospice care withdrawal and reinstatement from the informed consent requirements.

Removed requirement for informed consent to include attestation that all currently approved treatments are unlikely to prolong life.